Cargando…
Working towards a consensus for antibody validation
Commercial research antibodies are the most commonly used product in the life science tools market, and their applications represent a significant investment of time and resources for researchers. Frequently however, the quality of antibodies does not meet the expectations of consumers, causing loss...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288440/ https://www.ncbi.nlm.nih.gov/pubmed/25580232 http://dx.doi.org/10.12688/f1000research.5668.1 |
_version_ | 1782351973772689408 |
---|---|
author | Reiss, Peter D. Min, Danxi Leung, Mei Y. |
author_facet | Reiss, Peter D. Min, Danxi Leung, Mei Y. |
author_sort | Reiss, Peter D. |
collection | PubMed |
description | Commercial research antibodies are the most commonly used product in the life science tools market, and their applications represent a significant investment of time and resources for researchers. Frequently however, the quality of antibodies does not meet the expectations of consumers, causing loss of valuable time and money. This can delay research efforts and scientific discovery, or even lead to false, irreproducible results to be published in the scientific literature. This raises the question of whether there should be universal standards for validating antibodies. During the 1 (st) International Antibody Validation Forum, hosted by St John’s Laboratory Ltd on October 15 (th) 2014 at Queen Mary University of London, scientists from academia and industry presented data highlighting quality issues arising from lack of antibody validation. While the forum identified significant current problems in the antibody market, it also discussed future opportunities for improved quality and transparency by encouraging data disclosure and data sharing. This article highlights the key issues and conclusions reached at the forum. |
format | Online Article Text |
id | pubmed-4288440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-42884402015-01-09 Working towards a consensus for antibody validation Reiss, Peter D. Min, Danxi Leung, Mei Y. F1000Res Editorial Commercial research antibodies are the most commonly used product in the life science tools market, and their applications represent a significant investment of time and resources for researchers. Frequently however, the quality of antibodies does not meet the expectations of consumers, causing loss of valuable time and money. This can delay research efforts and scientific discovery, or even lead to false, irreproducible results to be published in the scientific literature. This raises the question of whether there should be universal standards for validating antibodies. During the 1 (st) International Antibody Validation Forum, hosted by St John’s Laboratory Ltd on October 15 (th) 2014 at Queen Mary University of London, scientists from academia and industry presented data highlighting quality issues arising from lack of antibody validation. While the forum identified significant current problems in the antibody market, it also discussed future opportunities for improved quality and transparency by encouraging data disclosure and data sharing. This article highlights the key issues and conclusions reached at the forum. F1000Research 2014-11-05 /pmc/articles/PMC4288440/ /pubmed/25580232 http://dx.doi.org/10.12688/f1000research.5668.1 Text en Copyright: © 2014 Reiss PD et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/publicdomain/zero/1.0/ Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). |
spellingShingle | Editorial Reiss, Peter D. Min, Danxi Leung, Mei Y. Working towards a consensus for antibody validation |
title | Working towards a consensus for antibody validation |
title_full | Working towards a consensus for antibody validation |
title_fullStr | Working towards a consensus for antibody validation |
title_full_unstemmed | Working towards a consensus for antibody validation |
title_short | Working towards a consensus for antibody validation |
title_sort | working towards a consensus for antibody validation |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288440/ https://www.ncbi.nlm.nih.gov/pubmed/25580232 http://dx.doi.org/10.12688/f1000research.5668.1 |
work_keys_str_mv | AT reisspeterd workingtowardsaconsensusforantibodyvalidation AT mindanxi workingtowardsaconsensusforantibodyvalidation AT leungmeiy workingtowardsaconsensusforantibodyvalidation |